Benefit of extending the dosing interval of paliperidone palmitate on schizophrenics with mild cognitive dysfunction

Asian J Psychiatr. 2017 Aug:28:98-99. doi: 10.1016/j.ajp.2017.03.033. Epub 2017 Mar 28.

Authors

Hidenobu Suzuki¹, Hiroyuki Hibino², Yuichi Inoue³, Ayako Mikami⁴, Hideo Matsumoto⁵, Katsunaka Mikami⁵

Affiliations

¹ Department of Psychiatry, Suzuki Clinic [H.S.], 3-34-16 Hamadayama, Suginami, Tokyo 168-0065, Japan. Electronic address: suzuhiromarket@yahoo.co.jp.
² Department of Psychiatry, Fukui Kinen Hospital [H.H.], Kanagawa 238-0115, Japan.
³ Department of Psychiatry, Shakomae Kokorono Clinic [Y.I.], Tokyo 116-0011, Japan.
⁴ Department of Data Science, Center for Clinical Science, National Center for Global Health and Medicine [A.M], Tokyo 162-8655, Japan.
⁵ Department of Psychiatry, Tokai University School of Medicine [H.M.], [K.M], Kanagawa 259-1193, Japan.

PMID: 28784410
DOI: 10.1016/j.ajp.2017.03.033

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antipsychotic Agents / administration & dosage*
Antipsychotic Agents / therapeutic use
Attention / drug effects
Cognitive Dysfunction / complications
Cognitive Dysfunction / drug therapy*
Cognitive Dysfunction / psychology
Drug Administration Schedule
Female
Humans
Memory, Short-Term / drug effects
Neuropsychological Tests
Paliperidone Palmitate / administration & dosage*
Paliperidone Palmitate / therapeutic use
Psychomotor Performance / drug effects
Reaction Time / drug effects
Schizophrenia / complications
Schizophrenia / drug therapy*
Schizophrenic Psychology
Speech / drug effects
Treatment Outcome
Young Adult

Substances

Antipsychotic Agents
Paliperidone Palmitate